MétaCan
Menu
Back to cohort

S3343 Biologic Therapy and Reactive Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

2021· article· en· W3209940673 on OpenAlexaboutno aff
Varun Jain, Esteban Figueroa, Brian Behm

Bibliographic record

VenueThe American Journal of Gastroenterology · 2021
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsnot available
Fundersnot available
KeywordsMedicinePrimary sclerosing cholangitisInflammatory bowel diseaseInternal medicineConcomitantTherapeutic drug monitoringRetrospective cohort studyUlcerative colitisGastroenterologyCohortCrohn's diseaseDiseasePharmacokinetics

Abstract

fetched live from OpenAlex

Introduction: Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD). Patients with concomitant PSC-IBD are at higher risk for IBD-related dysplasia and malignancy, however, the typical clinical IBD course is less severe. Recent years have seen increased biologic therapy use in IBD. As such, therapeutic drug monitoring (TDM) has also seen increased use, with reactive (rTDM) and proactive (pTDM) strategies being implemented in clinical care. The aim of this study was to identify the prevalence of biologic use and rTDM in a cohort of PSC-IBD patients. Methods: Retrospective analysis of patients with PSC-IBD on biologic therapy who underwent rTDM from Jan. 2018 to Aug. 2020 at the University of Virginia. Demographic data including age, disease duration, and comorbidities were recorded. IBD categorizations were recorded according to the Montreal Classification. Treatment outcomes including therapy changes after TDM were obtained. Results: 157 patients with PSC-IBD were identified. Of these, 29 patients (19%) were treated with biologic therapy during the study period. 13 patients underwent rTDM due to primary or secondary loss of response. An additional patient who underwent pTDM was identified but not included in the analysis. Median duration of IBD in this group was 9 years, and the median duration of concomitant PSC-IBD was 5.2 years. 19 TDM tests were obtained in these 13 patients. Of these, sub therapeutic drug levels were found in ten, and three detected anti-drug antibodies. Seven showed appropriate trough levels. TDM resulted in a change to IBD therapy (i.e. dose escalation, change in biologic therapy used, or addition of IBD medication) in 16 out of 19 tests. The remaining two resulted in no change to current therapy. Conclusion: Herein we describe epidemiologic data of biologic use in PSC-IBD patients at an academic center. PSC-IBD is thought to have a less severe clinical presentation and course. However, our experience demonstrates that a subset of PSC-IBD patients exists which require biologic therapy and have a more aggressive clinical course. In this subset, an rTDM strategy showed a high incidence of sub therapeutic trough levels and anti-drug antibodies, leading to optimization or change in therapy in over 80% of rTDM instances. Data on pTDM was limited in this study. Future studies should explore whether a pTDM strategy yields improved clinical outcomes in this special subset of PSC-IBD patients with a more aggressive phenotype.Table 1.: Demographic and clinical data.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.224
Teacher spread0.213 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicLiver Diseases and ImmunityFrench-language works237,207